Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

618
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
618
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

3.9K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
3.9K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

989
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
989
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

552
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
552
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

585
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
585
Dysrhythmias VII: Nursing Management of Dysrhythmias01:25

Dysrhythmias VII: Nursing Management of Dysrhythmias

525
Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...
525

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Impact of stent materials and hemodynamic changes after endovascular aneurysm repair for abdominal aortic aneurysm.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

Change in dapagliflozin trial eligibility status and prognosis among patients with acute heart failure with preserved ejection fraction.

Journal of the Chinese Medical Association : JCMA·2026
Same author

Cardiovascular benefits of early sodium-glucose cotransporter 2 inhibitor use for diabetics with acute myocardial infarction: A nationwide cohort study.

British journal of clinical pharmacology·2025
Same author

Management of HFpEF in Asian Patients: Evidence from Major Trials on HFpEF Therapeutics.

JACC. Asia·2025
Same author

A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure.

European journal of heart failure·2025
Same author

Differential Impacts of Resting and Exercise-related Blood Pressure Changes on Cardiovascular and All-cause Mortalities.

American journal of hypertension·2025

関連する実験動画

Updated: Apr 3, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K

心房細動の治療率と死亡率

Tze-Fan Chao1, Chia-Jen Liu1, Ta-Chuan Tuan1

  • 1From Division of Cardiology, Department of Medicine (T.-F.C., T.-C.T., K.-L.W., Y.-J.L., S.-L.C., L.-W.L., Y.-F.H., C.-E.C., S.-A.C.), Division of Hematology and Oncology, Department of Medicine (C.-J.L.), Division of Infectious Diseases, Department of Medicine (S.-J.C.), Department of Family Medicine (T.-J.C.), General Clinical Research Center (C.E.C.), and Department of Medical Research and Education (C.E.C.), Taipei Veterans General Hospital, Taipei, Taiwan; and Institute of Clinical Medicine and Cardiovascular Research Center (T.-F.C., T.-C.T., K.-L.W., Y.-J.L., S.-L.C., L.-W.L., Y.-F.H., C.-E.C., S.-A.C.) and Institute of Public Health and School of Medicine (C.-J.L., S.-J.C.), National Yang-Ming University, Taipei, Taiwan.

Circulation
|September 19, 2015
PubMed
まとめ

atrial fibrillationのレートコントロール治療,特にβ阻害剤とカルシウムチャネル阻害剤は,死亡率の低下と関連しています. しかし,心房細動患者におけるディゴキシンの使用は,死亡リスクの増加と関連していました.

キーワード:
アドレナージックβ抗体心房細動カルシウムチャネルブロッカーディゴキシン心拍数

さらに関連する動画

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.9K

関連する実験動画

Last Updated: Apr 3, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.9K

科学分野:

  • 心臓病科
  • 薬理学について
  • 公衆衛生

背景:

  • 現行のガイドラインでは,心房細動の治療にペースコントロールを推奨しています.
  • 速度制御薬の生存効果に関する証拠は限られている.
  • この研究は,レートコントロール薬を投与された患者と投与されなかった患者の予後を評価することを目的とした.

研究 の 目的:

  • 心房細動患者の全因死亡率との関連を調査する.
  • ベータ・ブロッカー,カルシウム・チャネル・ブロッカー,またはディゴキシンを投与した患者のアウトカムを対照群と比較する.

主な方法:

  • 大規模なコホート研究のために台湾の国立健康保険研究データベースを利用した.
  • 薬物の使用 (ベータブロッカー,カルシウムチャネルブロッカー,ディゴキシン,または無) によって分類された25万人を超える心房細動患者を含む.
  • ベースラインの差を調整し,死亡リスクの堅実な分析のための傾向マッチングを使用した.

主要な成果:

  • ベータブロッカーの使用は死亡率の有意な低下と関連していた (aHR=0. 76).
  • カルシウムチャネルブロッカーの使用も死亡リスクの低下を示した (aHR=0. 93).
  • ディゴキシンの使用は,あらゆる原因による死亡リスクの上昇と関連していた (aHR=1. 12).

結論:

  • ベータブロッカーまたはカルシウムチャネルブロッカーによるレートコントロール治療は,心房動の生存率の改善と関連しています.
  • ベータブロッカーは死亡リスクの最も顕著な減少を示した.
  • 死亡リスクが増加したため,心房細動患者におけるディゴキシンの使用は注意が必要であり,さらなるランダム化試験が必要です.